

# Determinants of normal puberty



**Professor  
David Dunger**

**European Society of  
Human Reproduction  
and Embryology**

**Budapest, 3<sup>rd</sup> December 2009**




# Determinants of normal puberty

- Endocrinology of puberty
- Timing of puberty
- Thelarche, pubarche and adrenarche




11.07.2005

# Luteinizing hormone (LH) pulsatility




Apter D, 1994, JCEM


## SECONDARY SEXUAL DEVELOPMENT




# Physiological effects of Testosterone




# Physiological effects of Oestrogen




## Fasting insulin




## IGF-I



## Growth Hormone




# Insulin Resistance of Puberty





Arslanian S & Kalhan S: Diabetes 43: 908, 1994

# Increased Insulin Secretion In Puberty



Caprio et al J Pediatr 114: 963, 1989

# Insulin levels and SHBG



● Females  
▲ Males

Holly et al. Clin Endocrinol 1989;31:277-284

# **Insulin resistance of puberty**

- 25-30% decrease insulin sensitivity
- Glucose uptake by muscle
- Post absorptive proteolysis
- Protein sparing 1g/Kg/d of FFM

**Puberty**

**16% mature height**

**Doubling of LBM**

# Puberty


16% Mature height

42% (Males)

47% (Females)



Adult weight

Doubling of LBM





Gender  
differences?

# Fat mass and Fat free mass in boys and girls



Ahmed et al. JCEM 1999;84:899-905


# Sex differences in leptin levels plotted against age and pubertal stage



Boys □ and ---  
Girls ● and —

Ahmed et al. JCEM 1999;84:899-905

# Peak Bone Mass




# Determinants of normal puberty

- Endocrinology of puberty
- Timing of puberty
- Thelarche, pubarche and adrenarche



# GONADOSTAT theory of regulation of LH control and timing of puberty



Grumbach et al; Control of the Onset of Puberty 1974

# **Genetic inheritance of puberty**

## **Mean difference in age at menarche**

**Unrelated women** 18.6 months

**Sisters** 12.9

**DZ twins** 12.0

**MZ twins** 2.2

**60-80% of the variance is familial**


# Age at Menarche

- He et al.
- Perry et al.
- Ong et al.
- Sulem et al.
- *LIN28B* shows similar sequence homology to the heterochronic gene *lin-28* in *C. elegans* (Guo et al, *Gene*, 2006).
- Mutations in *lin-28* produce abnormal rapid tempo of development through larval stages and adult cuticle development (Ambros et al, *Science*, 1984).
- Enhanced *lin-28* expression delays larval progression (Moss et al, *Cell*, 1997).
- *LIN28B* and *LIN28* encode potent and specific regulators of microRNA preprocessing (Viswanathan et al, *Science*, 2008), and regulate cell pluripotency and cancer growth (Guo et al, 2006).




*Caenorhabditis elegans*

# Historical trends in age at menarche



# Early maturation



- ↑ Childhood Ht BMI
- ↑ Childhood Ht gain
- Earlier puberty

*Birth      2 years      5 to 8 years*


**0.6 y boys**

**0.7 y girls**

- ↓ Pubertal Ht gain


# Rapid infancy growth → Earlier puberty

MRC 1946 Birth Cohort




dos Santos Silva et al. Int J Epidemiology 2002

# Age at menarche & obesity in ALSPAC mothers




# Offspring postnatal weight gain by mother's age at menarche




ALSPAC data

# Growth Hormone-Insulin Interaction



# Hypothesis: Age-specific effects of weight on puberty





# Determinants of normal puberty


- Endocrinology of puberty
- Timing of puberty
- Thelarche, pubarche and adrenarche



# Normal girls: Adrenal Androgens, longitudinal changes



# Postnatal catch-up growth




*Birth*

*2 years*

*5 to 8 years*

**Obesity  
Insulin resistance  
Thelarche  
Adrenarche**



Ong et al. J Clin Endocrinol Metab 2004;89:2647--2651

# Precocious Adrenarche / Pubarche

- Onset of pubic hair < 8yrs (girls)
- Bone Age advance
- Raised DHEA and DHEAS
- Final height not compromised

Increased risks in low birth weight


populations for:

- Functional ovarian hyperandrogenism
- PCOS
- Syndrome X

# PCOS after Precocious Pubarche: Relation to Reduced Fetal Growth

Birthweight

SDS



\*  $p \leq 0.01$   
± Std. Dev.  
± Std. Err.  
■ Mean

Precocious Pubarche

n = 31

Ovarian Hyperandrogenism-


n = 25

Severe Hyperinsulinemia

n = 12

n = 11

**Excess shorter AR CAG alleles ( $\leq$  20 repeats) in Spanish PP women (37%) vs. Spanish controls (25%,  $p=0.002$ )**



All Spanish women vs. UK control women ( $p<0.0005$ )

# Barcelona Precocious Pubarche Cohort

## *Aromatase Haplotypes*

Haplotype	Controls	Precocious Pubarche	Odds Ratio
AAGG**	26 (9%)	58 (16%)	2.5 (1.4~4.4)
AGGG*	78 (26%)	69 (18%)	1.0
AGGT	45 (15%)	50 (13%)	1.3 (0.8~2.1)
GAGG	116 (39%)	150 (40%)	1.5 (1.0~2.2)
others	35 (12%)	47 (13%)	~


Overall p<0.0001; \*p<0.05, \*\*p<0.01

# Determinants of normal puberty

- Endocrinology of puberty
- Timing of puberty
- Thelarche, pubarche and adrenarche



Age of Pubertal Onset and Menarche in White Girls			Breast stage 2		Menarche	
Studies:	N	mean	sd	mean	sd	
Reynolds and Wines 1948	49	10.8	1.1	12.9	1.4	
Marshall and Tanner 1969	192	11.15	1.10	13.47		
Roche et al 1995	67	11.2	0.7			
Herman-Giddens 1997	15,439	9.96	1.82	12.88	1.20	
Whincup 2001	1068			12.9	12.8-13.1	
Sun et al 2002, NHANES III:	594					
Median age at entry into stage 2		10.38	10.1-10.65			
Mean age for being in stage 2		11.05	0.18 (se)			
Freedman et al 2002, Bogalusa:						
1973/1974	1398	10.4		12.7	12.6-12.9	
1992-1994	1230			12.5	12.4-12.8	
Chumlea et al 2003, NHANES III:		10.4	10.1-10.7	12.55	12.31-12.79	
Anderson et al 2003						
1963-70, NHES II, III	1454			12.8	12.73-12.87	
1988-1994, NHANES III	452			12.6	12.48-12.71	



# **Adverse outcomes of early puberty:**

- **Increased adolescent risk-taking behaviour**
- **Shorter adult stature**
- **Increased adult BMI, waist circumference and adiposity**
- **Increased risk of adult-onset diabetes (owing to elevated BMI)**
- **Increased cardiovascular disease risk markers (including insulin resistance, blood pressure and metabolic syndrome)**
- **Increased risk of premenopausal breast cancer**
- **Increased all-cause mortality**

# **Determinants of normal puberty**


- **Role of weight gain/insulin**
- **First genes related to menarche identified**
- **Developmental determinants of adult disease**
- **Sexual dimorphism**
- **Timing of puberty and adult physiology**



# Acknowledgements



- Ken Ong




- Francis de Zegher




- Lourdes Ibáñez



- Marcus Pembrey
- Jean Golding



# GH/IGF-I axis and beta cell function




- IGF-I and beta cell function
- Beta cell mass
- Growth hormone

# GH – IGF-I axis

## Growth Hormone


### Growth Hormone



- Insulin antagonist
- Beta cell mass?

IGF-I


### IGF-I




- Insulin sensitisor
- Beta cell function?

Growth

# The GH/ IGF-1 axis in Type 1 DM




# Regional plot of the locus around *LIN28B* associated with age at menarche




Ong et al 2009 Nature Genetics 41:729-733

# Meta-analysis of the effect of each C allele at rs314276 in LIN28B on earlier age at menarche




# Survival in pre-pubertal status (Tanner breast stage 1) by age and *LIN28B* rs314276 genotype in ALSPAC girls ( $N=3,233$ )



Ong et al 2009 Nature Genetics 41:729-733

# Adolescent growth in ALSPAC girls by *LIN28B* rs314276 genotype



Ong et al 2009 Nature Genetics 41:729-733

# Non Obese Adolescents with HA with and without ovarian PCO

N	Total 86	Non-PCO 53	PCO 33	P
Age at PCO assessment (yr)	17 ± 0.2 *	17 ± 0.3	18 ± 0.4	NS
Age at menarche (yr)	11.8 ± 0.1	11.8 ± 0.1	11.7 ± 0.2	NS
Testosterone (ng/dL)	84 ± 4	85 ± 5	84 ± 5	NS
DHEAS (μg/dL)	251 ± 10	246 ± 14	259 ± 16	NS
FSH (IU/L)	5.1 ± 0.2	5.1 ± 0.2	5.1 ± 0.4	NS
LH (IU/L)	8.4 ± 0.6	7.6 ± 0.7	9.8 ± 1.2	NS
Birthweight (Kg)	3.0 ± 0.1	2.9 ± 0.1	3.3 ± 0.1	< 0.0005
Body Mass Index (Kg/m <sup>2</sup> )	22.9 ± 0.3 *	22.3 ± 0.4	23.9 ± 0.5	< 0.01
HOMA-IR	3.0 ± 0.2	2.7 ± 0.2	3.5 ± 0.3	< 0.01
Androstenedione (ng/dL)	353 ± 14	332 ± 17	389 ± 22	< 0.05
SHBG (μg/dL)	1.0 ± 0.1	1.1 ± 0.1	0.8 ± 0.1	< 0.05

Values are mean ± SEM

# **Developmental Origins of PCO and PCOS**

## **Differential developmental pathways**

- Low BW              In development of PCOS
- High BW             With and without PCO
- Parallels U-shaped risk for T2D

**Implications for definition of PCOS and treatment**

# PCOS Criteria


## In Adults: Rotterdam 2003

- Oligo/anovulation *and/or*
- Clinical and/or biochemical signs of HA
- Polycystic ovaries by u/s

## In Adolescents: No established diagnostic criteria

- Anovulation is common for 2 years post menarche, so difficult to differentiate if PCOS
- Multifollicular ovaries common in adolescence
- Transvaginal u/s not appropriate, difficult to image in obese adolescents
- Difficult to define androgen excess due to lack of normative data
- Normal insulin resistance of puberty

# Childhood height relative to mid-parental height, by pattern of infant weight gain



# Childhood height relative to mid-parental height, by mother's age at menarche

